48 new shares raised more than $11 billion! Under the outbreak, U.S. stocks biopharmaceutical IPO again boom.

Guide: The number of U.S. biopharmaceutical IPOs in 2020 has exceeded that of the whole of 2019, raising more than $11 billion.
2020 is undoubtedly a year of booming biopharmaceutical IPOs, the first half of this year due to the outbreak of stimulation, pharmaceutical and medical, life and health sectors more and more market attention.
48 biopharmaceutical companies listed in the U.S. by August 21, more than the total number of IPOs for the whole of 2019, according to Endpoints News, which raised $11,375 million.
that the biotechnology and pharmaceutical sectors are under sustained capital attention.
source: Endpoints News, 38 of the 48 companies, saw their prices rise by an average of 85 per cent as of August 21, while eight companies saw their shares rise by more than 100 per cent. Vaxcyte, Keros Therapeutics, Berkeley Lights, Alx Oncology and ADC Therapeutics. In addition, only five companies fell more than 20 percent, with Poseida Therautics falling the most because the FDA suspended a Phase 1 clinical trial of the company for metastatic prostate cancer.
that a patient died of liver failure 17 days after receiving BCMA CAR-T therapy.
, the new crown vaccine developer, has risen more than 300 per cent since CureVac was launched on August 14 at $16 a share.
Founded in 2000, CureVac's products include the drug candidates CV8102 and CV7202.
CV8102 is in the first phase of trials of solid tumors, and CV7202 is undergoing the first phase of trials of rabies vaccine.
CureVac is also promoting its mRNA vaccine program for the new coronavirus, which launched a trial in June 2020 among healthy volunteers and is expected to receive results in the fourth quarter of 2020.
Once CureVac's vaccine for the new coronavirus is successfully developed, it will be a boon for Europe and the United States, and even the world, so the expectations are high, making CureVac sought after by overseas investors.
June 2020, the German government announced a 300 million euro injection into CureVac to prevent it from being acquired by the United States.
2020, British pharmaceutical giant GlaxoSmithKline injected 130 million pounds into CureVac.
June-July 2020, CureVac completed $640 million in financing, more than all previously disclosed financings, including the Federal Government of Germany, GlaxoSmithKline and the Qatar Investment Authority.
Nanjing Legendary Biotech, the largest IPO, announced an initial public offering of 18.425 million American Depositary Shares (ADS) at $23 a share on June 5, US time, raising about $487.3 million.
biopic's IPO became the largest in the U.S. biotech sector since the start of the year in 2020.
founded in November 2014 as a global clinical phase biopharmaceutical company, Legendary Creatures is a subsidiary of Kingsley Biotech (01584.HK) dedicated to the discovery and development of new cell therapies for cancer, blood and infectious diseases.
Legendary Bio's ability to stage the 2020 IPO of its largest biotech company on NASDAQ is largely due to the stunning clinical trial data of car-T therapy LCAR-B38M/JNJ-4528 targeting BCMA (B-cell mature antigen) and endorsements from the leading multinational drug company, Johnson and Johnson.
2020 U.S. stock market and venture technology companies investment enthusiasm into 2020, the sudden rise in tension in the Middle East in early January will become the stock market's biggest "black swan", but in late January, an unexpected outbreak of new coronavirus-induced pneumonia outbreak rapidly heated up, and then become a global public health event, people are surprised.
U.S. stocks affected by this, the three major stock indexes volatility.
but at the same time, pharmaceutical stocks and biotech companies are "out of the question" in the outbreak, which has received particular attention from investors.
fact, in recent years, biotech companies have listed in the United States, especially on NASDAQ, and the investment market is very hot.
2019, the U.S. biotech sector as a whole rose strongly, as a "anti-economic cycle" of the higher degree of industry, medical sector companies even if the future economic growth slows, the government and residents of health care spending is not likely to shrink.
's strong momentum in 2019 stems from growing consumer awareness of health care and increased interest in new technologies such as capital to fight cancer.
2020, when pharmaceutical IPOs hit record highs, there was no shortage of market pursuits, both familiar and smaller, vaccine concept stocks.
the same time, some in the market have seen the risk of flashing behind the heat.
investment depends on poor expectations, and the current biopharmaceutical stocks have been basically expected to be priced, once the vaccine is available, effective, universal promotion, then pharmaceutical stocks may even fall back.
because expectations are too high, people all over the world have been looking forward to a year, so high expectations, once landed will turn into a profit.
, Russian President Vladimir Putin announced that Russia's first new crown vaccine "satellite V" has been registered with the state, although many people question the safety and verse of the vaccine, but the Russian vaccine is like a catfish, whether he succeeds or not, will greatly shorten the time of the vaccine, originally expected to be in the middle of next year, now expected to be ahead of time.
the necessary market risks, we should guard against them early.
source 1. New Crown vaccine developer CureVac listing: up 249% market value of nearly $10 billion 3. Legendary Bio landed in the U.S. stock market, the largest biotech IPO in 2020.